Boston Scientific announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in San Francisco on May 4-7
Data from the EFFORTLESS study, the first large-scale, multi-national, post-market analysis of afety and efficacy of the subcutaneous implantable defibrillator (S-ICD), will be featured at the late-breaking clinical trial session on Friday, May 6. Other presentations and abstracts of interest include:
New, pre-clinical data showcasing the company's modular therapy approach and communications compatibility between its leadless pacemaker and the EMBLEM™ S-ICD System Insights and results of the mapping data obtained using the high-density, high-resolution
Rhythmia™ Mapping System
Performance and usage information about the ACUITY™ X4 Quadripolar left ventricular (LV) l eads, which were approved by the U.S. Food and Drug Administration (FDA) earlier this year
Cost-effectiveness and safety data related to the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device
"We are enthusiastic about the breadth of robust data that we will be presenting at this year's congress, especially the data related to the performance of the S-ICD during the late-breaking clinical trial session" said Kenneth Stein, M.D., chief medical officer, Rhythm Management, Boston Scientific. "We are eager to present new evidence supporting our modular approach to leadless pacing and defibrillation, as well as proof that our mapping technology continues to set new standards of performance in the electrophysiology space."
ABSTRACTS OF INTEREST (listed chronologically within product categories)
Subcutaneous Implantable Defibrillator (S-ICD)
Session: The Subcutaneous ICD: Improving Efficacy, on Thursday, May 5 from 1:30 – 3:00 PM, in room 2014, Moscone West.
First Report On Communicating Leadless Anti-Tachycardia Pacemaker and Subcutaneous Implantable Defibrillator: Fleur V. Tjong, M.D., will present at 2:30 PM.
Late-Breaking Clinical Trial: Performance and Outcomes in Patients with the Subcutaneous Implantable Defibrillator Through Mid Term Follow-Up: The EFFORTLESS Study: Lucas V. A. Boersma, M.D., Ph.D., will present on Friday, May 6 at 1:45 PM in room 135, Moscone North.
Rhythmia Mapping System
Voltage threshold for high density mapping catheter with short interspaced small electrodes:Frederic Sacher, M.D., Ph.D., will present on Thursday, May 5 at 1:45 PM in room 3014, Moscone West.
High-Resolution mapping of Complex Left Atrial Tachycardia: Initial Experience with the Rhythmia Mapping System: Nicolas Derval, M.D., will present on Friday, May 6 at 2:30 PM in room 2006, Moscone West.
Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Implantable Defibrillator (ICD)
Incidence and Predictors of Phrenic Nerve Stimulation following Cardiac Resynchronization Therapy System Implantation of a Quadripolar Lead: Devi G. Nair, M.D., will present onFriday, May 6 at 1:45 PM in room 2010, Moscone West.
Performance and Usage of Proximal Electrodes in Quadripolar Left Ventricular Pacing Leads: Are All Leads Created Equally?: A poster authored by Nigel Gupta, M.D., will be available for viewing on Friday, May 6 from 2:00 PM – 5:00 PM in the EPicenter, Hall D.
The economic impact of longevity of implantable cardioverter-defibrillator for cardiac resynchronization therapy from a healthcare service perspective: A poster authored byMaurizio Landolina, M.D., will be available for viewing on Saturday, May 7 from 9:00 AM –12:00 PM in the EPicenter, Hall D.
WATCHMAN LAAC Device
Safety of Watchman Implantation when Performed with Uninterrupted Warfarin: A poster authored by Douglas N. Gibson, M.D., will be available for viewing on Friday, May 6 from 9:00 AM – 12:00 PM in the EPicenter, Hall D. mation about the ACUITY™ X4 Quadripolar left ventricular (LV) l eads, which were approved by the U.S. Food and Drug Administration (FDA) earlier this year
A Cost Analysis of Stroke in Non-valvular Atrial Fibrillation: Left Atrial Appendage Closure versus Warfarin versus Non-warfarin Oral Anticoagulants: A poster authored by Stacey Amorosi, M.A., and Vivek Y. Reddy, M.D., will be available for viewing on Friday, May 6 from2:00 PM – 5:00 PM in the EPicenter, Hall D.
All presentations are listed in Pacific Time and will take place at Moscone Center. For more information, visit Boston Scientific at booth #1805.
The company will also host an investor event and webcast on May 5 from 2:00 – 3:30 PM PDT to provide a presentation and answer questions from investors about the Boston Scientific rhythm management portfolio. The event will be accessible via live webcast at www.bostonscientific.com/investors . A replay of the webcast will be accessible at www.bostonscientific.com/investors beginning approximately one hour following the completion of the event.
Caution: The leadless pacemaker is a concept device or technology and not available for use or sale.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com
Boston Scientific Corporation
(651) 582-4251 (office)
Susie Lisa, CFA
Boston Scientific Corporation
(508) 683-5565 (office)
SOURCE Boston Scientific Corporation